Subgroups | No. of studies | OR | 95Â % CI | P value | Heterogeneity (I2) |
---|---|---|---|---|---|
Clinical node status | |||||
 Negative | 14 | 2.56 | 1.88–3.49 | <0.05 | 48.7 |
 Positive | 1 | 1.42 | 0.68–2.96 | >0.05 | – |
 Mixed | 4 | 1.93 | 0.99–3.76 | >0.05 | 59.5 |
NAC | |||||
 Before NAC | 6 | 2.96 | 1.78–4.94 | <0.05 | 15.6 |
 After NAC | 3 | 1.53 | 0.94–2.47 | >0.05 | 31.6 |
Proportion of patients with positive LSG | |||||
 ≥ 90 % | 7 | 1.41 | 0.83–2.39 | >0.05 | 22.1 |
 < 90 % | 6 | 2.99 | 1.99–4.48 | <0.05 | 42.8 |
Data source | |||||
 RCT | 6 | 2.25 | 1.23–4.11 | <0.05 | 74.7 % |
 NPS | 18 | 1.96 | 1.40–2.74 | <0.05 | 62.5 % |
Sample size | |||||
 > 300 | 15 | 2.01 | 1.42–2.84 | <0.05 | 75.9 % |
 < 300 | 9 | 2.01 | 1.28–3.15 | <0.05 | 7.0 % |
Location | |||||
 USA | 8 | 1.33 | 0.82–2.16 | >0.05 | 80.1 % |
 Europe | 11 | 2.48 | 1.60–3.84 | <0.05 | 43.7 % |
 Asia | 5 | 2.93 | 2.05–4.19 | <0.05 | 1.3 % |
Injection site of blue dye | |||||
 Superficial | 10 | 1.95 | 0.93–4.08 | >0.05 | 70.6 % |
 Deep | 9 | 2.76 | 2.32–3.30 | <0.05 | 0 |
Injection site of radioisotope | |||||
 Superficial | 9 | 2.05 | 0.87–4.84 | >0.05 | 76.0 % |
 Deep | 11 | 2.55 | 1.93–3.37 | <0.05 | 31.2 % |